Cross-species transfer of viruses: Implications for the use of viral vectors in biomedical research, gene therapy and as live-virus vaccines

Journal of Gene Medicine

Volumn 7, Issue 10, 2005, Pages 1263-1274

  Louz, Derrick ^a   Bergmans, Hans E ^a   Loos, Birgit P ^a   Hoeben, Rob C ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adaptation; Cross species transfer; Gene therapy; Gene transfer vector; Virology; Zoonosis

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; LIVE VACCINE; ONYX 015; RECOMBINANT DNA; THYMIDINE KINASE; VIRUS VECTOR;

ADAPTATION; ARBOVIRUS; AVIAN INFLUENZA; CROSS INFECTION; DISEASE CARRIER; DNA MODIFICATION; DNA VIRUS; GENE THERAPY; GENE TRANSFER; GENETIC VARIABILITY; H5N1 VIRUS; HANTAVIRUS; HENDRA VIRUS; HERPES SIMPLEX VIRUS; HOST RANGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION COMPLICATION; INFLUENZA VIRUS A; MEDICAL RESEARCH; MONKEYPOX VIRUS; NIPAH VIRUS; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RNA VIRUS; SARS CORONAVIRUS; SPECIES TRANSLOCATION; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; ZOONOSIS;

ANIMALS; BIOMEDICAL RESEARCH; DNA VIRUSES; EVOLUTION, MOLECULAR; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HIV INFECTIONS; HUMANS; INFLUENZA A VIRUS; RISK; RNA VIRUSES; VACCINES, ATTENUATED; VIRAL PHYSIOLOGY; VIRAL VACCINES; ZOONOSES;

ADENOVIRIDAE; ANIMALIA; ARBOVIRUS; AVES; AVIAN INFLUENZA VIRUS; COXSACKIEVIRUS; DNA VIRUSES; HANTAVIRUS; HENDRA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZAVIRUS A; MAMMALIA; MONKEYPOX VIRUS; NIPAH VIRUS; RNA VIRUSES; SARS ASSOCIATED CORONAVIRUS; SARS CORONAVIRUS; SIMPLEXVIRUS;

EID: 27644493612     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.794     Document Type: Review

References (145)

1. Murphy FA. New, emerging, and reemerging infectious diseases. Adv Virus Res 1994; 43: 1-52.
2. Pollard AJ, Dobson SR. Emerging infectious diseases in the 21st century. Curr Opin Infect Dis 2000; 13: 265-275.
3. Mahy BW, Brown CC. Emerging zoonoses: crossing the species barrier. Rev Sci Technol 2000; 19: 33-40.
4. Reed KD, Melski JW, Graham MB, et al. The detection of monkeypox in humans in the western hemisphere. N Engl J Med 2004; 350: 342-350.
5. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300: 1394-1399.
6. Flint SJ, Enquist LW, Krug RM (eds). Principles of Virology: Molecular Biology, Pathogenesis, and Control, ASM Press: Washington, DC, 2000.
7. Morse SS, Schluederberg A. Emerging viruses: the evolution of viruses and viral diseases. J Infect Dis 1990; 162: 1-7.
8. Weiss RA. The Leeuwenhoek Lecture 2001. Animal origins of human infectious disease. Philos Trans R Soc Lond B Biol Sci 2001; 356: 957-977.
9. Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis 1995; 1: 7-15.
10. Cohen ML. Changing patterns of infectious disease. Nature 2000; 406: 762-767.
11. Daszak P, Cunningham AA, Hyatt AD, et al. Emerging infectious diseases of wildlife - threats to biodiversity and human health. Science 2000; 287: 443-449.
12. Kruse H, kirkemo AM, Handeland K, et al. Wildlife as source of zoonotic infections. Emerg Infect Dis 2004; 10: 2067-2072.
13. Osterhaus A. Catastrophes after crossing species barriers. Philos Trans R Soc Lond B Biol Sci 2001; 356: 791-793.
14. Ludwig B, Kraus FB, Allwinn R, et al. Viral zoonoses - a threat under control? Intervirology 2003; 46: 71-78.
15. Kilbourne ED. New viruses and new disease: mutation, evolution and ecology. Curr Opin Immunol 1991; 3: 518-524.
16. Drake JW. The distribution of rates of spontaneous mutation over viruses, prokaryotes, and eukaryotes. Ann N Y Acad Sci 1999; 870: 100-107.
17. Smith DB, Inglis SC. The mutation rate and variability of eukaryotic viruses: an analytical review. J Gen Virol 1987; 68: 2729-2740.
18. Eigen M. On the nature of virus quasispecies. Trends Microbiol 1996; 4: 216-218.
19. Clarke DK, Duarte EA, Moya A, et al. Genetic bottlenecks and population passages cause profound fitness differences in RNA viruses. J Virol 1993; 67: 222-228.
20. Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol 1997; 51: 151-178.
21. Holland JJ, de la Torre JC, Steinhauer DA, et al. RNA virus populations as quasispecies. Curr Topics Microbiol Immunol 1992; 176: 1-20.
22. Meyers G, Rumenapf T, Tautz N, et al. Insertion of cellular sequences in the genome of bovine viral diarrhea virus. Arch Virol Suppl 1991; 3: 133-142.
23. Kilbourne ED. New viral diseases. A real and potential problem without boundaries. J Am Med Assn 1990; 264: 68-70.
24. Truyen U, Gruenberg A, Chang SF, et al. Evolution of the feline-subgroup parvoviruses and the control of canine host range in vivo. J Virol 1995; 69: 4702-4710.
25. Parrish CR, Have P, Foreyt WJ, et al. The global spread and replacement of canine parvovirus strains. J Gen Virol 1988; 69: 1111-1116.
26. Truyen U, Geissler K, Parrish CR, et al. No evidence for a role of modified live virus vaccines in the emergence of canine parvovirus J Gen Virol 1998; 79: 1153-1158.
27. Truyen U, Parrish CR. Canine and feline host ranges of canine parvovirus and feline panleukopenia virus: distinct host cell tropisms of each virus in vitro and in vivo. J Virol 1992; 66: 5399-5408.
28. Parrish CR, Burtonboy G, Carmichael LE, et al. Characterization of a nonhemagglutinating mutant of canine parvovirus. Virology 1988; 163: 230-232.
29. Hueffer K, Parker JS, Weichert WS, et al. The natural host range shift and subsequent evolution of canine parvovirus resulted from virus-specific binding to the canine transferrin receptor. J Virol 2003; 77: 718-1726.
30. Parrish CR, Aquadro CF, Strassheim ML, et al. Rapid antigenic-type replacement and DNA sequence evolution of canine parvovirus. J Virol 1991; 65: 6544-6552.
31. Mochizuki M, Harasawa R, Nakatani H, et al. Antigenic and genomic variabilities among recently prevalent parvoviruses of canine and feline origin in Japan. Vet Microbiol 1993; 38: 1-10.
32. Truyen U, Evermann JF, Vieler E, et al. Evolution of canine parvovirus involved loss and gain of feline host range. Virology 1996; 215: 186-189.
33. Ikeda Y, Nakamura K, Miyazawa T, et al. Feline host range of canine parvovirus: recent emergence of new antigenic types in cats. Emerg Infect Dis 2002; 8: 341-346.
34. Truyen U. Emergence and recent evolution of canine parvovirus: Vet Microbiol 1999; 69: 47-50.
35. Hueffer K, Parrish CR. Parvovirus host range, cell tropism and evolution. Curr Opin Microbiol 2003; 6: 392-398.
36. Hahn BH, Shaw GM, De Cock KM, et al. AIDS as a zoonosis: scientific and public health implications. Science 2000; 287: 607-614.
37. Sharp PM, Bailes E, Chaudhuri RR, et al. The origins of acquired immune deficiency syndrome viruses: where and when? Philos Trans R Soc Lond B Biol Sci 2001; 356: 867-876.
38. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999; 397: 436-441.
39. Santiago ML, Rodenburg CM, Kamenya S, et al. SIVcpz in wild chimpanzees. Science 2002; 295: 465.
40. Chen Z, Luckay A, Sodora DL, et al. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys. J Virol 1997; 71: 3953-3960.
41. Gao F, Yue L, White AT, et al. Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature 1992; 358: 495-499.
42. Holmes EC. On the origin and evolution of the human immunodeficiency virus (HIV). Biol Rev Camb Philos Soc 2001; 76: 239-254.
43. Korber B, Muldoon M, Theiler J, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000; 288: 1789-1796.
44. Lemey P, Pybus OG, Wang B, et al. Tracing the origin and history of the HIV-2 epidemic. Proc Natl Acad Sci U S A 2003; 100: 6588-6592.
45. Wain-Hobson S. Immunodeficiency viruses. 1959 and all that. Nature 1998; 391: 531-532.
46. Zhu T, Korber BT, Nahmias AJ, et al. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature 1998; 391: 594-597.
47. Wolfe ND, Switzer WM, Carr JK, et al. Naturally acquired simian retrovirus infections in central African hunters. Lancet 2004; 363: 932-937.
48. Marx PA, Alcabes PG, Drucker E, et al. Serial human passage of simian immunodeficiency virus by unsterile injections and the emergence of epidemic human immunodeficiency virus in Africa. Philos Trans R Soc Lond B Biol Sci 2001; 356: 911-920.
49. Weiss RA. Natural and iatrogenic factors in human immunodeficiency virus transmission. Philos Trans R Soc Lond B Biol Sci 2001; 356: 947-953.
50. Preston BD, Poiesz BJ, Loeb LA, et al. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242: 1168-1171.
51. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 1582-1586.
52. Perrin L, Kaiser L, Yerly S, et al. Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 2003; 3: 22-27.
53. Rambaut A, Posada D, Crandall KA, et al. The causes and consequences of HIV evolution. Nat Rev Genet 2004; 5: 52-61.
54. Weiss RA. Gulliver's travels in HIVland. Nature 2001; 410: 963-967.
55. Webster RG, Bean WJ, Gorman OT, et al. Evolution and ecology of influenza A viruses. Microbiol Rev 1992; 56: 152-179.
56. Nicholson KG, Wood JM, Zambon M, et al. Influenza. Lancet 2003; 362: 1733-1745.
57. Beare AS, Webster RG. Replication of avian influenza viruses in humans. Arch Virol 1991; 119: 37-42.
58. Hinshaw VS, Webster RG, Naeve CW, et al. Altered tissue tropism of human-avian reassortant influenza viruses. Virology 1983; 128: 260-263.
59. Ito T, Couceiro JN, Kelm S, et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol 1998; 72: 7367-7373.
60. Webby RJ, Webster RG, et al. Emergence of influenza A viruses. Philos Trans R Soc Lond B Biol Sci 2001; 356: 1817-1828.
61. Kawaoka Y, Krauss S, Webster RG, et al. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 1989; 63: 4603-4608.
62. Scholtissek C, Rohde W, Von HV, et al. On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology 1978; 87: 13-20.
63. Reid AH, Taubenberger JK. The origin of the 1918 pandemic influenza virus: a continuing enigma. J Gen Virol 2003; 84: 2285-2292.
64. Reid AH, Taubenberger JK, Fanning TG, et al. Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus. Nat Rev Microbiol 2004; 2: 909-914.
65. Hatta M, Kawaoka Y. The continued pandemic threat posed by avian influenza viruses in Hong Kong. Trends Microbiol 2002; 10: 340-344.
66. Connor RJ, Kawaoka Y, Webster RG, et al. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 1994; 205: 17-23.
67. Rogers GN, Paulson JC, Daniels RS, et al. Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity. Nature 1983; 304: 76-78.
68. Vines A, Wells K, Matrosovich M, et al. The role of influenza A virus hemagglutinin residues 226 and 228 in receptor specificity and host range restriction. J Virol 1998; 72: 7626-7631.
69. Matrosovich M, Zhou N, Kawaoka Y, et al. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol 1999; 73: 1146-1155.
70. Horimoto T, Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev 2001; 14: 129-149.
71. Webster RG. Wet markets - a continuing source of severe acute respiratory syndrome and influenza? Lancet 2004; 363: 234-236.
72. Domingo E. Quasispecies and the implications for virus persistence and escape. Clin Diagn Virol 1998; 10: 97-101.
73. Lai MM, Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res 1997; 48: 1-100.
74. Baric RS, Yount B, Hensley L, et al. Episodic evolution mediates interspecies transfer of a murine coronavirus. J Virol 1997; 71: 1946-1955.
75. Baric RS, Sullivan E, Hensley L, et al. Persistent infection promotes cross-species transmissibility of mouse hepatitis virus. J Virol 1999; 73: 638-649.
76. Chen W, Yount B, Hensley L, et al. Receptor homologue scanning functions in the maintenance of MHV-A59 persistence in vitro. Adv Exp Med Biol 1998; 440: 743-750.
77. Schickli JH, Thackray LB, Sawicki SG, et al. The N-terminal region of the murine coronavirus spike glycoprotein is associated with the extended host range of viruses from persistently infected murine cells. J Virol 2004; 78: 9073-9083.
78. Logan D, Abu-Ghazaleh R, Blakemore W, et al. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 1993; 362: 566-568.
79. Mason PW, Grubman MJ, Baxt B, et al. Molecular basis of pathogenesis of FMDV. Virus Res 2003; 91: 9-32.
80. Jackson T, Ellard FM, Ghazaleh RA, et al. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J Virol 1996; 70: 5282-5287.
81. Sa-Carvalho D, Rieder E, Baxt B, et al. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol 1997; 71: 5115-5123.
82. Baranowski E, Ruiz-Jarabo CM, Sevilla N, et al. Cell recognition by foot-and-mouth disease virus that lacks the RGD integrin-binding motif: flexibility in aphthovirus receptor usage. J Virol 2000; 74: 1641-1647.
83. Martinez MA, Verdaguer N, Mateu MG, et al. Evolution subverting essentiality: dispensability of the cell attachment Arg-Gly-Asp motif in multiply passaged foot-and-mouth disease virus. Proc Natl Acad Sci U S A 1997; 94: 6798-6802.
84. Neff S, Sa-Carvalho D, Rieder E, et al. Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor. J Virol 1998; 72: 3587-3594.
85. Ruiz-Jarabo CM, Pariente N, Baranowski E, et al. Expansion of host-cell tropism of foot-and-mouth disease virus despite replication in a constant environment. J Gen Virol 2004; 85: 2289-2297.
86. Cole CN, Conzen SD. Polyomaviridae: the viruses and their replication. In Fields Virology (4th edn). Knipe DM, Howley PM (eds). Lippincott Williams & Wilkins: Philadelphia, 2001; 2141-2174.
87. Aneskievich BJ, Taichman LB. Evidence for two points of restriction in the expression of adenovirus type 2 in cultured epidermal keratinocytes. J Virol 1988; 62: 4365-4368.
88. Klessig DF. Isolation of a variant of human adenovirus serotype 2 that multiplies efficiently on monkey cells. J Virol 1977; 21: 1243-1246.
89. Freimuth P. A human cell line selected for resistance to adenovirus infection has reduced levels of the virus receptor. J Virol 1996; 70: 4081-4085.
90. Shukla D, Spear PG. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest 2001; 108: 503-510.
91. Nixdorf R, Schmidt J, Karger A, et al. Infection of Chinese hamster ovary cells by pseudorabies virus. J Virol 1999; 73: 8019-8026.
92. Schmidt J, Klupp BG, Karger A, et al. Adaptability in herpesviruses: glycoprotein D-independent infectivity of pseudorabies virus. J Virol 1997; 71: 17-24.
93. Schmidt J, Gerdts V, Beyer J, et al. Glycoprotein D-independent infectivity of pseudorabies virus results in an alteration of in vivo host range and correlates with mutations in glycoproteins B and H. J Virol 2001; 75: 10 054-10 064.
94. Spear PG, Eisenberg RJ, Cohen GH, et al. Three classes of cell surface receptors for alphaherpesvirus entry. Virology 2000; 275: 1-8.
95. Sinzger C, Schmidt K, Knapp J, et al. Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. J Gen Virol 1999; 80: 2867-2877.
96. Hoffmann E, Neumann G, Kawaoka Y, et al. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 2000; 97: 6108-6113.
97. Pleschka S, Jaskunas R, Engelhardt OG, et al. A plasmid-based reverse genetics system for influenza A virus. J Virol 1996; 70: 4188-4192.
98. Hatta M, Gao P, Halfmann P, et al. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 2001; 293: 1840-1842.
99. Kobasa D, Takada A, Shinya K, et al. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 2004; 431: 703-707.
100. Tumpey TM, Garcia-Sastre A, Taubenberger JK, et al. Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A 2004; 101: 3166-3171.
101. Hatta M, Neumann G, Kawaoka Y, et al. Reverse genetics approach towards understanding pathogenesis of H5N1 Hong Kong influenza A virus infection. Philos Trans R Soc Lond B Biol Sci 2001; 356: 1841-1843.
102. Furminger IG. Immunoglobuln synthesis after immunization with human wart virus. Prog Immunobiol Stand 1970; 4: 166-173.
103. Hoffmann E, Krauss S, Perez D, et al. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 2002; 20: 3165-3170.
104. Senne DA, Panigrahy B, Kawaoka Y, et al. Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Dis 1996; 40: 425-437.
105. Subbarao K, Chen H, Swayne D, et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003; 305: 192-200.
106. Wood JM, Robertson JS. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2004; 2: 842-847.
107. Yount B, Curtis KM, Baric RS, et al. Strategy for systematic assembly of large RNA and DNA genomes: transmissible gastroenteritis virus model. J Virol 2000; 74: 10 600-10 611.
108. Yount B, Curtis KM, Fritz EA, et al. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA 2003; 100: 12 995-13 000.
109. Thiel V, Herold J, Schelle B, et al. Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus. J Gen Virol 2001; 82: 1273-1281.
110. Masters PS. Reverse genetics of the largest RNA viruses. Adv Virus Res 1999; 53: 245-264.
111. de Haan CA, van Genne L, Stoop JN, et al. Coronaviruses as vectors: position dependence of foreign gene expression. J Virol 2003; 77: 11 312-11 323.
112. Enjuanes L, Sola I, Almazan F, et al. Coronavirus derived expression systems. J Biotechnol 2001; 88: 183-204.
113. Sola I, Alonso S, Zuniga S, et al. Engineering the transmissible gastroenteritis virus genome as an expression vector inducing lactogenic immunity. J Virol 2003; 77: 4357-4369.
114. Haijema BJ, Volders H, Rottier PJ, et al. Switching species tropism: an effective way to manipulate the feline coronavirus genome. J Virol 2003; 77: 4528-4538.
115. Kuo L, Godeke GJ, Raamsman MJ, et al. Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J Virol 2000; 74: 1393-1406.
116. Ebert D. Experimental evolution of parasites. Science 1998; 282: 1432-1435.
117. Pratt WD, Davis NL, Johnston RE, et al. Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models. Vaccine 2003; 21: 3854-3862.
118. Afzal MA, Pickford AR, Forsey T, et al. The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. J Gen Virol 1993; 74: 917-920.
119. Galler R, Post PR, Santos CN, et al. Genetic variability among yellow fever virus 17D substrains. Vaccine 1998; 16: 1024-1028.
120. Ryman KD, Xie H, Ledger TN, et al. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology 1997; 230: 376-380.
121. Wright KE, Dimock K, Brown EG, et al. Biological characteristics of genetic variants of Urabe AM9 mumps vaccine virus. Virus Res 2000; 67: 49-57.
122. Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001; 358: 98-104.
123. Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001; 358: 91-97.
124. Ries SJ, Brandts CH, Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov Today 2004; 9: 759-768.
125. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 2002; 83: 491-502.
126. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004; 6: S164-S171.
127. St George JA. Gene therapy progress and prospects: adenoviral vectors. Gene Ther 2003; 10: 1135-1141.
128. Tomko RP, Xu R, Philipson L, et al. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
129. Wickham TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
130. Amalfitano A, Parks RJ. Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr Gene Ther 2002; 2: 111-133.
131. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005; 12: 141-161.
132. Kirn D, Martuza RL, Zwiebel J, et al. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001; 7: 781-787.
133. Schneider-Schaulies J. Cellular receptors for viruses: links to tropism and pathogenesis. J Gen Virol 2000; 81: 1413-1429.
134. Baranowski E, Ruiz-Jarabo CM, Domingo E, et al. Evolution of cell recognition by viruses. Science 2001; 292: 1102-1105.
135. Field H, Young P, Yob JM, et al. The natural history of Hendra and Nipah viruses. Microbes Infect 2001; 3: 307-314.
136. Engelthaler DM, Mosley DG, Cheek JE, et al. Climatic and environmental patterns associated with hantavirus pulmonary syndrome, Four Corners region, United States Emerg Infect Dis 1999; 5: 87-94.
137. Rappole JH, Derrickson SR, Hubalek Z, et al. Migratory birds and spread of West Nile virus in the western hemisphere. Emerg Infect Dis 2000; 6: 319-328.
138. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000; 81: 2573-2604.
139. Jones N, Shenk T. Isolation of deletion and substitution mutants of adenovirus type 5. Cell 1978; 13: 181-188.
140. Haj-Ahmad Y, Graham FL. Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene. J Virol 1986; 57: 267-274.
141. Roelvink PW, Mi LG, Einfeld DA, et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999; 286: 1568-1571.
142. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
143. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
144. Freytag SO, Rogulski KR, Paielli DL, et al. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-1333.
145. Yamamoto M, Davydova J, Wang M, et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003; 125: 1203-1218.